Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: B01AB02

ATryn(antithrombin alfa)

Antithrombin III Deficiency

Marketing Authorisation Holder: Laboratoire Francais du Fractionnement et des Biotechnologies

EMA Authorisation: 28/07/2006

INN: antithrombin alfa

Indication

ATryn is indicated for the prophylaxis of venous thromboembolism in surgery of patients with congenital antithrombin deficiency. ATryn is normally given in association with heparin or low molecular weight heparin.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about ATryn — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.